ArticleFluids and barriers of the CNS2017
The MRZ reaction in primary progressive multiple sclerosis.
Article in Fluids and barriers of the CNS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- The Use of Nitrosative Stress Molecules as Potential Diagnostic Biomarkers in Multiple Sclerosis.International journal of molecular sciences · 2024Pooled it
- The Presence of MRZ Reactions Improves the Prediction of Multiple Sclerosis in Children with Optic Neuritis.Children (Basel, Switzerland) · 2025Article
- CHARACTERISTICS OF SPEECH AND SWALLOWING IN PERSONS WITH MULTIPLE SCLEROSIS.Acta clinica Croatica · 2024Review
- Antibody Cross-Reactivity in Auto-Immune Diseases.International journal of molecular sciences · 2023Review
- Diagnostic Cerebrospinal Fluid Biomarker in Early and Late Onset Multiple Sclerosis.Biomedicines · 2022Article
- Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis.EXCLI journal · 2021Review
- Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.Cells · 2020Article
- The Challenge of Assessing Mild Neuroinflammation in Severe Mental Disorders.Frontiers in psychiatry · 2020Review
- Epstein-Barr Virus and Multiple Sclerosis.Frontiers in immunology · 2020Review
- Immune-Mediated Control of a Dormant Neurotropic RNA Virus Infection.Journal of virology · 2019Article
- The MRZ-Reaction and Specific Autoantibody Detection for Differentiation of ANA-Positive Multiple Sclerosis From Rheumatic Diseases With Cerebral Involvement.Frontiers in immunology · 2019Article
- The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.Journal of neurology · 2018Article
- Progress in brain barriers and brain fluid research in 2017.Fluids and barriers of the CNS · 2018Article
- Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.Journal of neurology · 2018Review
- The MRZ reaction helps to distinguish rheumatologic disorders with central nervous involvement from multiple sclerosis.BMC neurology · 2018Article
- Do patients with schizophreniform and bipolar disorders show an intrathecal, polyspecific, antiviral immune response? A pilot study.Fluids and barriers of the CNS · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe MRZ reaction (MRZR), composed of the three antibody indices (AI) against measles, rubella and varicella zoster virus and found positive in the majority of relapsing-remitting multiple sclerosis (RRMS) patients, is absent in other inflammatory neurological diseases (OIND). So far, it has been uncertain whether its differential diagnostic promise extends to patients with primary-progressive multiple sclerosis (PPMS).
objectiveTo investigate the prevalence of MRZR in PPMS compared to RRMS and OIND patients.
methodsMRZR was assessed in patients with PPMS (n = 103), RRMS (n = 100) and OIND (n = 48). Both stringency levels for MRZR testing, MRZR-1 (≥1 AI positive) and MRZR-2 (≥2 AI positive), were applied.
resultsPrevalence of positive MRZR-1 was 83.5% in PPMS and 67.8% in RRMS (p < 0.05). A positive MRZR-2 was found in 54.4% of PPMS and in 43.0% of RRMS patients (not significant). Compared to both MS subgroups, OIND patients exhibit lower frequencies of positive MRZR (MRZR-1: 22.9%, MRZR-2: 8.3%; p < 0.0001 each).
conclusionPositive MRZR was at least as frequent in PPMS as in RRMS and much less frequent in OIND, confirming its promise as a potentially useful diagnostic tool for distinguishing both MS course types from OIND.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.